- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04630288
Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome
ANTIPLATELET TREATMENT IN ACUTE CORONARY SYNDROMES. SAFETY AND EFFICACY OF ANTIPLATELET SWITCHING Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To date, there are still a paucity of data on the medium- and long-term safety and efficacy outcomes of new antiplatelet agents, namely Ticagrelor and Prasugrel, compared to Clopidogrel in a real-world ACS setting.
The ARIAM-Andalusia multicentre Registry, and the CREA-ARIAM multicentre Registry (ClinicalTrials.gov Identifier: NCT02500290; Fundación Pública Andaluza Progreso y SaludIdentifier: FPS-AAS-2014-01), are two Real World Evidence (RWE) studies aimed to investigate real-world practice on antiplatelet treatment in patients with ACS in Andalusia (Western Spain).
Our group are interested in performing a retrospective observational pilot analysis using data from patients with ACS admitted to cardiovascular intensive care units in Andalusia (Spain), who were prospectively included in the ARIAM-Andalusia multicentre Registry, and the CREA-ARIAM multicentre Registry (ClinicalTrials.gov Identifier: NCT02500290; Fundación Pública Andaluza Progreso y Salud-Identifier: FPS-AAS-2014-01) between 2014 and March 2019. The main findings from the RWE study revealed a consistent net clinical benefit of Ticagrelor vs Clopidogrel resulted in a significant reduction of short-term all-cause mortality favored Ticagrelor. In this scenario, after baseline imbalance adjustment using propensity score matching (PSM) and IPTW (inverse probability of treatment weight) methods, the net clinical benefit with Ticagrelor persisted. Preliminary results of the above mentioned study have been presented as an oral communication at the Annual Scientific Meeting of the Spanish Society of Cardiology (Madrid, October 2017).
The aim of this new pilot study suggested is to describe the efficacy and safety of Ticagrelor vs Clopidogrel after the first 30 days from hospital discharge and up to 1 year follow-up.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Sevilla, Spain
- Hospital Universitario Virgen Macarena
-
Sevilla, Spain, 41092
- Fundación Pública Progreso y Salud
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
All-comers ACS population (with or without ST segment elevation, including unstable angina) with:
A recent CCU admission (patients included in the ARIAM-CREA study within 1 week from the index ACS admission between March 1, 2015 to March 31, 2018), irrespective of either the initial management (invasive or non-invasive) or the revascularization procedure (PCI with stenting or CABG) discharged on DAPT including either Ticagrelor or Clopidogrel and have survived the first 30-day follow-up period from the index ACS event and could complete a 12-month follow-up.
Exclusion Criteria:
- Age < 18 years.
- Subjects who died in the first 30-day follow-up period from the index ACS event, including those who died during the index admission.
- A medical condition likely to limit survival to less than 1 year.
- Any factors judged by the local investigators to be likely to limit adherence to pharmacological treatment.
- Failure to obtain informed consent from participant.
- Currently enrolled in an interventional clinical research trial involving an investigational product (drug) or device
- Not available for follow-up over a minimum of 365 days, e.g. no fixed home address.
- Pregnancy, breast-feeding, or intend to become pregnant during the study period population should be always considered as exclusion criterion.
- Non-ACS diagnosis at discharge, i.e., acute myocarditis, Takotsubo syndrome, pulmonary thromboembolism or acute aortic syndromes.
- Myocardial infarction secondary to an ischaemic imbalance or type 2 myocardial infarction (Third Universal Definition of MI), in instances of myocardial injury with necrosis, where a condition other than CAD contributes to an imbalance between myocardial oxygen supply and/or demand, i.e., anaemia, sepsis, tachyarrhythmias, hypotension, heart failure…
- Patients not discharged on dual antiplatelet therapy (DAPT) consistent on low dose of ASA plus a P2Y12platelet receptor inhibitor (Clopidogrel or Ticagrelor)
- Patient discharged on DAPT including Prasugrel as the P2Y12 inhibitor drug.
- Hypersensitivity to ticagrelor or any of the excipients.
- Active pathological bleeding.
- History of intracranial haemorrhage (ICH).
- Severe hepatic impairment.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Clopidogrel
Clopidogrel is a prodrug that requires metabolic activation in two stepsby hepatic CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.
The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
Consequently, due to the irreversible binding to the P2Y12 receptor,platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days) and recovery of normal platelet function occurs at a rate consistent with the normal platelet turnover.
Clopidogrel was approved by the European Commission on 15 July 1998 for the secondary prevention of atherothrombotic events in adult patients with ACS.
|
Describe the safety of Ticagrelor vs Clopidogrel use, in patients with ACS in terms of major bleeding between 30 days and one year after the index ACS event.
An ITT approach and IPCW method to adjust for change of initial treatment will be used for the analysis.
|
Ticagrelor
Ticagrelor is a nucleoside analogue member of the chemical class cyclopentyltriazolopyrimidines (CPTP), which is a selective and reversible ADP- receptor antagonist acting on the platelet P2Y12 receptor.
This prevents the binding of ADP to the receptor which attenuates plateletactivation and aggregation.The drug was approved by the European Commission on December 3, 2010, for the prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in patients with ACS (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]) including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
|
Describe the safety of Ticagrelor vs Clopidogrel use, in patients with ACS in terms of major bleeding between 30 days and one year after the index ACS event.
An ITT approach and IPCW method to adjust for change of initial treatment will be used for the analysis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major bleeding
Time Frame: During 2 months
|
Defined as BARC type≥ 3 according to the Bleeding Academic Research Consortium (BARC) definition at 1-year follow-up after the index ACS.
|
During 2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Thrombolysis in Myocardial Infarction (TIMI)
Time Frame: During 2 months
|
Bleeding criteria
|
During 2 months
|
BARC definition
Time Frame: During 2 months
|
Bleeding criteria
|
During 2 months
|
Major Adverse Cardiac and Cerebrovascular Events (MACCE)
Time Frame: During 2 months
|
Defined as the composite of all-cause mortality, myocardial infarction (MI), target lesion revascularization (TLR), stent thrombosis and stroke or TIA at 1-year follow-up after the index ACS admission.
|
During 2 months
|
All-cause mortality
Time Frame: During 2 months
|
Component of MACCE
|
During 2 months
|
Myocardial infarction
Time Frame: During 2 months
|
Component of MACCE
|
During 2 months
|
Target lesion revascularization
Time Frame: During 2 months
|
Component of MACCE
|
During 2 months
|
Stent thrombosis
Time Frame: During 2 months
|
Component of MACCE
|
During 2 months
|
Stroke
Time Frame: During 2 months
|
Component of MACCE
|
During 2 months
|
Net clinical benefit/Net Adverse Clinical Event (NACE):
Time Frame: During 2 months
|
Defined as the composite of the efficacy (Major Adverse Cardiac and Cerebrovascular Events-MACCE) and safety (BARC type≥ 2 bleeding episodes according to the Bleeding Academic Research Consortium (BARC) definition for bleeding) outcomes at 1 year after the index ACS.
|
During 2 months
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Disease
- Syndrome
- Acute Coronary Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Ticagrelor
- Clopidogrel
Other Study ID Numbers
- FPS-AAS-2019-01 (ESR-17-13127)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndromes
-
Lene HolmvangCompletedCoronary Artery Disease | Percutaneous Coronary Intervention | Acute Coronary SyndromesDenmark
-
Virginia Commonwealth UniversityBracco Diagnostics, IncTerminatedCoronary Artery Disease | Acute Coronary SyndromesUnited States
-
Shanghai Zhongshan HospitalActive, not recruiting
-
AstraZenecaCompletedAcute Coronary SyndromesKorea, Republic of
-
Yaling HanUnknownAcute Coronary SyndromesChina
-
Xijing HospitalUnknown
-
Dr. Sanjit S. JollyMcMaster University; Population Health Research InstituteCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Shenyang Northern HospitalUnknownAcute Coronary SyndromesChina
Clinical Trials on Clopidogrel
-
Korea University Anam HospitalCompleted
-
Chinese PLA General HospitalUnknownCLOPIDOGREL, POOR METABOLISM of (Disorder)China
-
Ospedale San DonatoCompletedAcute Myocardial InfarctionItaly
-
University of PecsTerminatedStable Angina Pectoris | Ad Hoc Percutaneous Coronary InterventionHungary
-
Hospital Central San Luis Potosi, MexicoUnknownAcute Coronary Syndrome
-
University of North Carolina, Chapel HillCompleted
-
Lady Reading Hospital, PakistanPakistan Chest Society, PakistanRecruitingCOPD | COPD Exacerbation AcutePakistan
-
Deutsches Herzzentrum MuenchenTerminatedCoronary Artery DiseaseGermany
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaCompleted